Profund Advisors LLC boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 30,912 shares of the biopharmaceutical company’s stock after acquiring an additional 1,774 shares during the quarter. Profund Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $2,466,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Alnylam Pharmaceuticals in the first quarter valued at approximately $148,000. Westpac Banking Corp bought a new position in Alnylam Pharmaceuticals in the first quarter valued at approximately $202,000. Prudential Financial Inc. bought a new position in Alnylam Pharmaceuticals in the first quarter valued at approximately $215,000. CIBC Asset Management Inc bought a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $221,000. Finally, Neuberger Berman Group LLC bought a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $229,000. 94.27% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts recently issued reports on ALNY shares. Piper Jaffray Companies set a $116.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 24th. ValuEngine cut shares of Alnylam Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 27th. Janney Montgomery Scott started coverage on shares of Alnylam Pharmaceuticals in a research note on Friday, June 2nd. They issued a “sell” rating and a $67.00 price objective on the stock. Chardan Capital set a $110.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, June 12th. Finally, BidaskClub raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 13th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the stock. Alnylam Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $81.11.

Shares of Alnylam Pharmaceuticals, Inc. (ALNY) traded down 2.48% during trading on Friday, hitting $76.21. 1,348,848 shares of the stock were exchanged. The firm’s market capitalization is $6.99 billion. Alnylam Pharmaceuticals, Inc. has a 52 week low of $31.38 and a 52 week high of $89.45. The stock’s 50 day moving average price is $81.55 and its 200 day moving average price is $68.51.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The business had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. During the same period in the prior year, the business posted ($1.05) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% on a year-over-year basis. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post ($5.18) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/09/17/alnylam-pharmaceuticals-inc-alny-position-lifted-by-profund-advisors-llc.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.